A CDMO partnership shows how gene therapy manufacturing is scaling for chronic disease
Dr. Dereck Mush, MD, MBA
What they do
Francis Medical announced a financing agreement led by Johnson & Johnson Innovation, JJDC on November 10, 2026. The amount was not disclosed. Funding supports Vanquish System commercial expansion, physician training and the planned PMA submission for management of clinically localized prostate cancer. This planned indication is not represented as already authorized.
The record
- Vertical
- Devices & Robotics
- Sub-segment
- Urological therapy
- Product type
- Device
- Stage
- Headquarters
- Maple Grove, Minnesota, United States
- Region
- North America
- Founded
- Not disclosed
- Total funding
- Undisclosed
Also in Devices & Robotics
Related on The Signal
Dr. Dereck Mush, MD, MBA
Industrializing Cell and Gene Therapy: The Economics of Multiply Labs' $75M Robotic Cleanroom Clusters
Dr. Dereck Mush, MD, MBA
CDMOs race to add capacity as cell and gene therapy demand outpaces supply
Dr. Dereck Mush, MD, MBA
After the Ablation: StimCardio, Wearable Neuromodulation and the Next AF Outcome Gap
Dr. Dereck Mush, MD, MBA